What Are Yervoy's Serious Side Effects?
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, triggers immune-related adverse events (irAEs) by overactivating the immune system. Serious effects include severe colitis (leading to bowel perforation), hepatitis (liver inflammation), endocrinopathies (thyroid or pituitary issues), pneumonitis (lung inflammation), and skin reactions like Stevens-Johnson syndrome. These can be life-threatening, affecting up to 40% of patients in trials, with grade 3-4 events in 15-20%.[1][2]
How Are Serious irAEs Managed During Treatment?
Management follows stepwise guidelines from the manufacturer and NCCN. Hold Yervoy for moderate irAEs (grade 2) and permanently discontinue for severe (grade 3-4) or recurrent cases.
- Colitis/Diarrhea: Start high-dose corticosteroids (1-2 mg/kg/day prednisone equivalent). If no improvement in 3 days, add infliximab (5 mg/kg IV). Avoid antidiarrheals alone, as they mask progression. Monitor with frequent stool tests and endoscopy.[2][3]
- Hepatitis: Corticosteroids first; mycophenolate mofetil if elevated liver enzymes persist. Avoid other hepatotoxins.[2]
- Endocrinopathies: Hormone replacement (e.g., levothyroxine for hypothyroidism, hydrocortisone for adrenal insufficiency). Do not taper steroids abruptly.[3]
- Pneumonitis: High-dose steroids; consider infliximab or mycophenolate if needed. Use CT scans and bronchoscopy for diagnosis.[2]
Infliximab or vedolizumab is reserved for steroid-refractory cases, especially GI toxicity. All patients get premed education on symptoms like persistent diarrhea or fatigue.
When Do Doctors Restart Yervoy After Side Effects?
Restart only if irAEs resolve to grade 0-1 and corticosteroids are tapered to ≤10 mg/day prednisone. Permanent discontinuation is standard for grade 4 events or multiple grade 3 recurrences. About 20-30% of patients resume after holding.[3]
What Monitoring Helps Prevent Escalation?
Baseline and periodic labs (liver enzymes, thyroid function, CBC) plus clinical checks every 2-3 weeks during induction (four 3 mg/kg doses every 3 weeks). Patient diaries track symptoms. Early intervention cuts severe event rates by 50% in studies.[1][2]
How Does Combination with Other Drugs Affect Management?
In Yervoy + Opdivo (nivolumab) regimens, irAEs occur in 50-60% of patients, often dual-organ. Same steroid-first approach, but higher vigilance for myocarditis or neurologic toxicity. Guidelines emphasize multidisciplinary input (e.g., gastroenterology consults).[3]
What Do Patients Experience Long-Term?
Some irAEs persist post-treatment, like hypothyroidism (10-15% permanent). Late-onset effects (e.g., hypophysitis) appear months later. Regular endocrine follow-up is key; taper steroids slowly to avoid flares.[2]
[1]: Bristol Myers Squibb, Yervoy Prescribing Information (FDA-approved label).
[2]: NCCN Guidelines for Melanoma, Version 2.2024.
[3]: Hodi FS et al., N Engl J Med 2010;363:711-23 (key Yervoy trial data).